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Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S129complete the planned therapy due to ear discomfort. The rest
completed therapy without subsequent treatment limiting
toxicity. For the eleven patients who were assessed for
engraftment, the median time to neutrophil count recovery
was day 11 (10-13) and for platelet count recovery was day
16 (14-19) post-transplant. In this unplanned interim anal-
ysis, the historical control group was estimated to have a
longer average time to neutrophil recovery (0.15 days with a
standard error of 0.32) and a longer average log-transformed
time to platelet recovery (approximately 0.16 log-days with a
standard error of 0.08), which transformed into days repre-
sents about 1.2 days.
Conclusion: HBO therapy prior to PBSC cell infusion appears
to be well tolerated in the setting of high-dose therapy and
autologous PBSC transplantation. HBO impact on blood count
recovery should be investigated further.
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Introduction: Poor peripheral blood stem cell (PBSC)
mobilization has been shown to be associated with worse
outcomes in lymphoma patients undergoing autologous
stem cell transplantation (ASCT). The impact of poor mobi-
lization on the outcome of ASCT in multiple myeloma (MM)
patients has not been well studied. In this single institution
retrospective study, we evaluated the effect of poor mobili-
zation on PFS and OS for MM patients undergoing ASCT.
Methods:We collected data retrospectively for patients with
MMwho underwent ASCT between Jan. 2001 and Dec. 2010.
Patients were initially mobilized with standard-dose (10
mcg/kg/day) granulocyte colony stimulating factor. Patients
were classiﬁed as poor mobilizers if they failed to collect >
4106 CD34+ cells/kg from all apheresis attempts. The log-
rank test was used to analyze PFS (from ASCT to ﬁrst relapse)
and OS (from diagnosis to death) for both groups. Multivar-
iate analysis by the Cox proportional hazards model was
used to assess the correlation of mobilization with other
known prognostic variables and PFS and OS.
Results: Total of 271 patients were identiﬁed for study in-
clusion. Of these, 13 patients were excluded due to loss of
follow-up beyond 6 months (8), progressive disease through
ASCT (3), development of secondmalignancies (2). The mean
length of follow-up for all patients was 74.5 months. Thirty-
seven (14.3%) patients were poor mobilizers and 221 (85.7%)
were good mobilizers. Univariate analysis showed no sig-
niﬁcant difference between the two groups in regards to age,
gender, beta-2 microglobulin (B2M) level at diagnosis, and
disease status at time of ASCT, but there was signiﬁcant dif-
ferences in disease stage at presentation (86.5% had Durie-
Salmon disease stage 3A or 3B vs. 63.8%, p ¼ 0.007), numberof prior chemotherapy regimens (67.6% had  2 prior regi-
mens vs. 43.8%, p ¼ 0.005), and ideal body weight (median
67.2 vs. 62.3 kg, p ¼ 0.015) in poor vs. good mobilizers,
respectively. Survival analysis for poor versus good mobi-
lizers showed a median PFS of 24.7 months vs. 28.7 months
(p¼ 0.08) and median OS of 52.8 months vs. 106.8 months (p
< 0.0001), respectively. Cox PH regression multivariate
analysis showed signiﬁcant correlation of PFS to disease
stage and number of prior chemotherapy regimens, while
B2M and number of prior chemotherapy regimens correlated
signiﬁcantly to OS. However, poor mobilization was not
signiﬁcantly correlated to PFS (p ¼ 0.963) or OS (p ¼ 0.087).
After ASCT, good mobilizers were more likely to be in VGPR/
CR than poor mobilizers (53.4 vs. 37.8%, respectively).
Conclusions: Poor PBSC mobilization is associated with
worse long-term outcomes inMMpatients undergoing ASCT.
Our data suggests that poor mobilization was not an inde-
pendent predictive factor, possibly due to small number of
patients, but signiﬁcantly associated with a more advanced
disease stage and  2 of pre-transplant chemotherapy regi-
mens.
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Background: Evidence based dosing of high-dose Cyclo-
phosphamide (Cy) in obese patients remains elusive and
some studies have identiﬁed obesity a risk factor for non-
relapse mortality (NRM). We studied an adjusted body
weight (ABW50) Cy dosing method in morbidly obese pa-
tients (body mass index >30) undergoing high dose Cy
conditioning and autologous HCT.
Patients & Methods: We analyzed 147 patients with non-
Hodgkin lymphoma (NHL) who received Cy (120 mg/kg IV) +
fractionated total body irradiation (TBI; 1320 cGy) condi-
tioning (2001e2012) in 3 groups divided by bodyweight: not
obese (<120% ideal body weight (IBW); n¼72), obese (120-
149% IBW; n¼46) and morbidly obese (150% IBW; n¼29).
Patients <150% of IBW were dosed using actual body weight
(ABW). In morbidly obese patients, total Cy was calculated
using adjusted body weight (ABW50) formula: IBW +
0.5(ABWeIBW). Patients had NHL (diffuse large B cell lym-
phoma n¼57, mantle cell lymphoma n¼51 and others n¼39)
with median age 57 years (range 19-73) and median follow
up 2 years (range 1-9 yrs).
Results: NRM at 1 year was 4% and not different in 3 weight
groups. Overall survival (OS) at 4 years for non-obese was
54% (95% CI 40-67), obese 64% (95% CI 44-79), morbidly
obese 64% (95% CI 37-82). Cumulative incidence of relapse
was similar in 3 groups: 46% (95% CI: 36-55%); 44% (95%
CI:28-60%) vs 48% (95% CI: 26-70%). Multivariable regression
showed similar OS and relapse when adjusted for gender and
disease status (Table). No differences were seen among
weight groups regarding incidence of neutrophil and
platelet engraftment, hemorrhagic cystitis or cardiac
toxicity (congestive heart failure).
Conclusion: We report the ﬁrst prospective testing of efﬁ-
cacy and safety of weight-adjusted correction of Cy dosing
Weight group n BMI Weight used for Cy dose Relapse Hazard ratio (95% CI) p-value Overall mortality Hazard ratio (95% CI) p-value
Non-obese
120% IBW
72 25 (19-28) ABW 1.00 1.00
Obese
121-149 IBW
46 29 (24-42) ABW 0.97 (0.55-1.74) 0.68 0.72 (0.37-1.4) 0.34
Morbidly obese
 150 IBW
29 36 (30-55) IBW + 0.5 (ABWeIBW) 0.78 (0.39-1.57) 0.32 0.65 (0.28-1.52) 0.32
IBW ideal body weight, ABW actual body weight.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146S130using ABW50 formula in morbidly obese receiving high-dose
Cy/TBI conditioning. Our data indicate that adjusted Cy
dosing yields similar relapse rate, OS and NRM with no sig-
niﬁcant impact on engraftment or toxicity. Morbidly obese
patients can safely receive adjusted dose Cy.Figure 1B. Overall survival.
Figure 1C. Landmark analysis for PFS after 1 yr of HR.
Figure 1A. Progression free survival.142
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Background: Light chain amyloidosis (AL) involves deposi-
tion of misfolded amyloid ﬁbrils in the affected organs,
including heart and kidneys, causing organ dysfunction. We
sought to determine if the concurrent cardiac and renal
involvement was associated with a worse outcome than
either organ alone.
Methods: We identiﬁed 129 patients (pts) with AL who
received high-dose chemotherapy followed by autologous
hematopoietic stem cell transplantation (auto-HCT) at our
institution between 1997 and 2014. Ninety-nine patients had
either renal (group 1: n¼62, 62%), cardiac (group 2: n¼20,
20%) or both renal and cardiac (group 3: n¼17, 17%)
involvement. Hematologic response (HR) was deﬁned ac-
cording to the international myeloma working group
(IMWG) criteria and organ response (OR) was deﬁned ac-
cording to consensus opinion from the 10th international
symposium on amyloid and amyloidosis (M Gertz et al. Am J
Hematol. 2005 Aug; 79[4]:319-28).
Results: The median age at auto-HCT for groups 1, 2 and 3
was 58, 60, and 53 years, respectively (p ¼ 0.30). The
median urine protein in groups 1, 2 and 3 was 5.5, 0.28
and 2.0 g/24h, respectively (p ¼ <0.0001). The medain
difference in involved and uninvolved free light
chain(dFLC) in groups 1, 2 and 3 was 37, 147 and 128,
respectively (p ¼ 0.10). The medain NT-Pro BNP (pg/ml) in
groups 2 and 3 was 1206 and 1766, respectively (p ¼ 1.0),
and median intraventricular septal thickness (cm) was 1.3
and 1.4, respectively (p ¼ 0.87). Mayo Cardiac stages for
patients in groups 2 and 3 were: stage 1; 4 (11%), stage 2;
13 (35%), stage 3; 7 (19%) and unavailable; 13 (35%).The
median time from diagnosis to auto-HCT in groups 1, 2
and 3 was 7 (2-120), 8 (3-35) and 6 (3-96) months,
respectively. The overall hematological response rate
(CR+VGPR+PR) in groups 1, 2 and 3 was 75%, 87.5% and
82% respectively (p ¼ 0.38). Organ response in groups 1, 2
and 3 was 40%, 40% and 70% respectively (p ¼ 0.002). Four(6%) patients in group 1, 0 in group 2 and 1 (6%) patient in
group 3 died of non-relapse causes (NRM) in the ﬁrst 100
days (p ¼ 0.66). The median progression free survival (PFS)
from auto-HCT in groups 1, 2 and 3 was not reached, 19.5
months, and 21 months respectively (p ¼ 0.035) (Fig. 1A).
The median overall survival (OS) in groups 1, 2 and 3 was
10, 4.3 and 5 years, respectively (p ¼ 0.035) (Fig. 1B). In a
landmark analysis for patients who were alive and in HR
at 1 year post auto-HCT, the median PFS in groups 1-3
was not reached, 37.5 and 21 months, respectively (p ¼
0.16) (Fig. 1C).
Conclusion: Patients with concurrent cardiac and renal AL
have similar PFS and OS as patients with cardiac AL alone, but
worse than patients with renal AL only. These patients may
potentially beneﬁt from auto-HCT.
